EFFECT OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP1) AGONIST LIRAGLUTIDE, ON BLOOD PRESSURE, GLUCOSE METABOLISM AND MODULATION OF TUBULAR FUNCTION AS MEASURED BY MICRORNAS IN AN EXPERIMENTAL MODEL OF HYPERTENSION AND INSULIN.

• Grant number: 22/09481-0
• Support Opportunities: Scholarships in Brazil - Master
• Start date: December 01, 2022
• End date: November 30, 2024
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Marcelo Costa Batista
• Grantee: Gabrielle Regis de Castro Barbosa
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• Associated research grant: 19/25493-6 - Obesity: pathophysiology and related therapeutic strategies, AP.TEM

Abstract

Insulin resistance, excess visceral fat and high blood pressure are clinical conditions thatdetermine risk factors for cardiovascular disease. Furthermore, when associated, theyproduce renal alterations that potentiate arterial hypertension, generate severalinflammatory mediators and determine a reduction in renal function. Experimentalmodels are extremely useful for studying the pathophysiology of these conditions. GLP1agonists, such as liraglutide, are potential drugs for reducing the deleterious effects ofmetabolic dysfunction and can contribute to the reduction of renal function. Thus, thisstudy aims to evaluate the effect of liraglutide on blood pressure, glucose and lipidmetabolism, renal functional parameters, and expression of microRNAs 34a (miRNA34a) and 145 (miRNA-145) in the renal tubule of hypertensive rats, obese and theirassociation. Therefore, SHR rats, who will or will not receive a high calorie diet, will betreated with liraglutide for 12 weeks. Blood pressure and body weight will be monitoredweekly and at the end of the period, glucose and insulin tolerance tests will be performed.Urine will also be collected in metabolic cages. After sacrifice, blood, visceral fat andkidney tissue will be collected for laboratory determinations.Keywords: SHR Inbreeding Rats, Insulin Resistance, Glucagon 1-like Peptide Receptor,miRNA-34A, miRNA-145.